By Michele Maatouk
Date: Wednesday 05 Aug 2026
(Sharecast News) - Eli Lilly lifted its full-year guidance on Wednesday as weight-loss jabs Mounjaro and Zepbound drove an increase in second-quarter sales.
| Currency | US Dollars |
| Share Price | $ 1,191.94 |
| Change Today | $ 22.08 |
| % Change | 1.89 % |
| 52 Week High | $1,235.56 |
| 52 Week Low | $625.65 |
| Volume | 2,662 |
| Shares Issued | 944.80m |
| Market Cap | $1,126,145m |
| RiskGrade | 179 |
| Time | Volume / Share Price |
| 16:04 | 358,940 @ $1,191.94 |
| 15:59 | 122 @ $1,192.52 |
| 15:59 | 90 @ $1,192.52 |
| 15:59 | 440 @ $1,192.52 |
| 15:59 | 40 @ $1,192.63 |
You are here: research